Treatment factors influencing survival in pancreatic carcinoma;Der einfluss der therapie auf das uberleben von patienten mit pankreaskarzinom: Eine analyse von einzelfaktoren

Strahlentherapie und Onkologie

Volumn 175, Issue 7, 1999, Pages 315-319

  Warszawski, Nathan ^a   Link, Karl Heinz ^a   Warszawski, Antje ^a   Lutz, Manfred Paul ^a   Gansauge, Frank ^a   Schneider, Bernd Michael ^a   Röttinger, Erwin M ^a  

^a NONE

Author keywords

Biologically effective dose Treatment volume; Chemotherapy; Pancreatic carcinoma; Radiotherapy; Resection; Survival

Indexed keywords

CISPLATIN; FLUOROURACIL; MITOXANTRONE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIVARIATE ANALYSIS; PANCREAS ADENOCARCINOMA; RADIATION DOSE; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE;

EID: 0032779465     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000660050017     Document Type: Article

References (29)

1. Bentzen SM, Thames HD. Clinical evidence for tumor clonogen regeneration: Interpretations of the data. Radiother Oncol 1991;22:161-6.
2. Bosset JF, Pavy JJ, Gillet M, et al. Conventional external irradiation alone as adjuvant treatment in resectable pancreatic cancer: results of a prospective study. Radiother Oncol 1992;24:191-4.
3. de Neve W, Lybeert MLM, Goor C, et al. Radiotherapy for T2 and T3 carcinoma of the bladder: The influence of overall treatment time. Radiother Oncol 1995;36:183-8.
4. Dobelbower RR, Borgelt BB, Strubler KA, et al. Precision radiotherapy of the pancreas: technique and results. Int J Radiat Oncol Biol Phys 1980;6:1127-33.
5. Dobelbower RR, Merrick HW, Khuder S, et al. Adjuvant radiation therapy for pancreatic cancer: a 15-year experience. Int J Radiat Oncol Biol Phys 1997;39:31-7.
6. Dubben HH, Thames HD, Beck-Bornholdt HP. Tumor volume: a basic and specific response in radiotherapy. Radiother Oncol 1998;47:167-74.
7. Flickinger JC, Jawalekar K, Deutsch M, et al. Split course radiation therapy for adenocarcinoma of the pancreas. . Int J Radiat Oncol Biol Phys 1988;15:359-64.
8. Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:457-67.
9. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679-94.
10. Hendry JH, Bentzen SM, Dale RG, et al. A modeled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol R Coll Radiol 1996;8:297-307.
11. Herrmann T, Jakubek A, Trott KR. The importance of the timing of a gap in radiotherapy of squamous cell carcinomas of the head and neck. Strahlenther Onkol 1994;170:545-9.
12. Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16:317-23.
13. Kato H, Wakasuki H, Yakota M, et al. Effectiveness of chemotherapy for advanced adenocarcinoma of the pancreas in combined modality therapy. Intern Med 1994;33:142-6.
14. Katz A, Hanlon A, Lanciano R, et al. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:393-6.
15. Latz D, Schraube P, Eble MJ. Primäre Strahlentherapie des inoperablen oder rezidivierten Pankreaskarzinoms - Heidelberger Krankengut von 1982 bis 1992. Strahlenther Onkol 1993:;169:387-93.
16. Lionetto R, Pugliese V, Bruzzi P, et al. No Standard treatment is available for advanced pancreatic cancer. Eur J Cancer 1995;31:882-7.
17. Maciejewski B, Makewski S. Dose fractionation and tumor repopulation in radiotherapy for bladder cancer. Radiother Oncol 1991;21:163-70.
18. Nishimura Y, Hosotani R, Shibamoto Y, et al. External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications. Int J Radiat Oncol Biol Phys 1997;39:39-49.
19. Peretz T, Nori D, Hilaris B, et al. Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys 1989;17:931-5.
20. Skladowski K, Law M, Maciejewski B, et al. Planned and unplanned gaps in radiotherapy: the importance of gap position and gap duration. Radiother Oncol 1994;30:109-20.
21. Stevenson JP, Scher RM, Kosierowski R, et al. Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. Eur J Cancer 1998;34:1358-62.
22. Tai P, Van Dyke J, Yu E, et al. Variability of target volume delineation in cervical esophageal cancer. Int J Radiat Oncol Biol Phys 1998;42:277-88.
23. Taylor JMG, Wendenhall WM, Lavey RS. Time-dose factors in positive neck nodes treated with irradiation only. Radiother Oncol 1991;22: 167-73.
24. The Gastrointestinal Tumor Study Group. Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. Cancer 1989;64:2010-3.
25. Thomas CR, Weiden PL, Traverso LW, et al. Concomitant intraarterial cisplatin, intravenous 5-fluorouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703). Am J Clin Oncol 1997;20:161-5.
26. UICC. TNM-Klassifikation maligner Tumoren, 5. Aufl. Berlin-Heidelberg-New York: Springer, 1997:84-7.
27. Ulmer Forschungsgruppe Onkologie Gastrointestinaler Tumoren (U-FOGT). Palliative Radiochemotherapie beim primär inoperablen Pankreaskarzinom: Intraarterielle Chemotherapie + Radiotherapie alternierend/kontinuierlich. Studienprotokoll 1995.
28. Wheldon TE, Deehan C, Wheldon EG, et al. The linear-quadratic transformation of dose-volume histograms in fractionated radiotherapy. Radiother Oncol 1998;46:285-95.
29. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27: 131-46.